Improving patient access to life-enhancing medications
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals.
We have a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world.
We offer patients better, safer & more accessible medicines.
To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.
Mayne Pharma has a full service contract development and manufacturing organisations (CDMO) specialising in novel oral and topical dose forms providing pharmaceutical development, analytical testing and commercial manufacturing to clients worldwide. Our mission is to partner with clients to develop and deliver pharmaceutical products from “concept to commercialisation” to change the lives of patients around the globe:
At Mayne Pharma, we recognise that we are part of a global community. As part of this community, we are committed to operating our business in a sustainable manner. We ensure our people are safe and well-supported, local communities prosper and the environment is well cared for so that it benefits future generations.
For investorsCompany Announcements
Mayne Pharma Q1 FY24 Trading Update
19 Oct 2023
Mayne Pharma CEO Shawn Patrick O’Brien said: “We are very pleased to report the progress of Mayne Pharma as we continue our transition phase and simplify our business. The first quarter of FY24 reflects the hard work undertaken to improve operating performance and drive revenue and margin. Our team are engaged to deliver on the potential of our portfolio in the markets we operate in.”
Mayne Pharma 2023 Full Year Results Media Release
2 Sep 2023
Mayne Pharma’s CEO, Mr Shawn Patrick O’Brien said, “Fiscal year 2023 has been one of significant change at Mayne Pharma."
Mayne Pharma Investor Update and On-Market Share Buy-Back Program
10 May 2023
Mayne Pharma’s CEO Mr. Shawn Patrick O’Brien said: “The past seven months have been a period of significant change for the Company, beginning with the October sale of our Greenville-based Metrics Contract Services, followed by the acquisition of the US commercial rights for TherapeuticsMD’s women’s health assets. With the recent sale of our retail generics business to Dr. Reddy’s, we are successfully executing on our strategy to become a more focused company, with growth potential while repaying debt, paying shareholders a special dividend, and strengthening our cash position in the process.”
Mayne Pharma completes sale of U.S. Generics Portfolio to Dr. Reddy’s
7 Apr 2023
Mayne Pharma’s CEO Mr Shawn Patrick O’Brien said: “The divestiture of our US retail generics portfolio is yet another milestone in the transformation of Mayne Pharma into a specialty pharmaceutical company in the US women’s healthcare and dermatology markets. We are excited by the significant opportunities to drive operational, commercial and financial improvements across our US women’s health and dermatology businesses, as well as in our International business. Our stated objectives remain to return the Company to profitability,to generate operating cash flow that supports further growth and to drive improved returns for our shareholders.”
Mayne Pharma 2023 Half Year Results Media Release
28 Feb 2023
Mayne Pharma’s CEO, Mr Shawn O'Brien said, “The performance of our business during the first half of FY23 is categorized by building momentum in our Branded Products Division."
Mayne Pharma announces sale of U.S. Generics Portfolio to Dr. Reddy’s
27 Feb 2023
Mayne Pharma’s CEO Mr. Shawn Patrick O’Brien said: “Divesting the retail generics portfolio is an important step forward for the Company as we continue to rationalise our portfolio. With this transaction, we free up working capital, allowing us to more exclusively focus resources on core areas of value for business growth, namely our branded verticals in US women's health and dermatology."